<DOC>
	<DOCNO>NCT00145691</DOCNO>
	<brief_summary>We intend conduct phase III b trial verify Oxcarbazepine 's effect agitation aggression patient dementia . We design study randomize , double-blind , placebo-controlled multi center trial . Hundred patient include . The treatment period eight week , follow four week . The primary outcome measure reduction aggression agitation measure mean NPI-NH-subscale agitation / aggression ( Neuropsychiatric Inventory , Nursing Home Version ) . Secondary outcome reduction aggression measure BARS ( Behavior Agitation Rating Scale ) reduction burden health-care personnel measure NPI-NH .</brief_summary>
	<brief_title>The Effect Oxcarbazepine Treatment Agitation / Aggression Dementia ( OBAD )</brief_title>
	<detailed_description>Inclusion criterion : Patients either gender , 55 year age old , live nursing home diagnose strong suspicion dementia Alzheimer ’ type vascular origin , BPSD form agitation / aggression measure subscale NPI-NH BARS . Exclusion criterion : Patients kind dementia FTD , PD LBD ; patient hepatic renal failure , disease make impossible follow study schedule ; patient antiepileptic antipsychotic .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Oxcarbazepine</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>Alzheimer ’ dementia , vascular dementia mix form accord ICD10 ( F00 , F01 ) criterion . The patient 55 year age older . Residents nurse home least 4 week prior inclusion . Signed informed consent patient relative sign agreement reservation patient ’ participation study . At least one week history agitation aggression , score 6 NPINHsubscale agitation/aggression . Previous intolerability know hypersensitivity Oxcarbazepine equivalent Low sodium serum level &lt; 135 mmol/L Severe impair renal function ( creatinine clearance &lt; 30 ml/min , calculate Cockroft + Gault ’ formula ) Hepatic failure ( transaminase ( gGT ALAT &gt; 3 time upper normal limit ) . Patients AVblock II III kinds arrhythmia necessitating treatment . Severe somatic disease afford change medication compromise attendance study . Patients cyclosporine . Patients need strong analgesic like opioids codeine Patients take carisoprodol Alcohol drug abuse last 12 month ( use high dosage prescribe ) The patient ChEIs memantine le 3 month change dosage last 2 week . The patient take antiepileptic antipsychotic ( may include two week use antipsychotic end ) . The patient take MAOI lithium The patient dementia type PDD , FTD DLB The patient severe acute neurological disease ( e.g . epilepsy , acute CVE , severe Parkinson ’ disease , acute confusion ) severe psychiatric disorder like bipolar disorder , schizophrenia ... The patient participate another clinical trial last 3 month . The patient randomize study .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
</DOC>